MUSTANG BIO, INC.
MBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on acquiring and developing novel cell and gene therapies for difficult-to-treat cancers, primarily through licensing partnerships with research institutions.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for MUSTANG BIO, INC..
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on acquiring and developing novel cell and gene therapies for difficult-to-treat cancers, primarily through licensing partnerships with research institutions.
- Mustang Bio is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for difficult-to-treat cancers [sec_mda · as of 2026-08-05].
- The company's pipeline is currently focused on novel therapies for solid tumors, with partnerships including City of Hope and Nationwide Children's Hospital [sec_mda · as of 2026-03-19].
- As of June 30, 2026, Mustang Bio reported cash and equivalents of $15.2 million, shareholders' equity of $9.5 million, and a net loss of $1.1 million for the quarter [sec].
- The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future, with substantial doubt about its ability to continue as a going concern [sec · filed 2025-01-15].
- Mustang Bio has not generated any revenue from its development-stage products and does not know when or if it will generate revenue [sec · filed 2025-01-15].
What works
- Mustang Bio has established partnerships with world-class research institutions such as City of Hope and Nationwide Children's Hospital, providing access to cutting-edge technologies [sec_mda · as of 2026-03-19].
- The company's strategy of licensing technologies and funding research allows it to leverage external expertise without bearing the full cost of early-stage discovery [sec_mda · as of 2026-08-05].
What to weigh
- Mustang Bio has incurred significant losses since inception and anticipates continued losses, with substantial doubt about its ability to continue as a going concern [sec · filed 2025-01-15].
- The company has no approved products and has not generated any revenue from its development-stage products, making its future uncertain [sec · filed 2025-01-15].
- Mustang Bio will need to raise additional financing in upcoming periods, which may not be available on acceptable terms or at all [sec · filed 2025-01-15].
From the filings
Quoted directly from source documents.
Mustang Bio is a clinical-stage biopharmaceutical company focused on difficult-to-treat cancers.
“We are a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers.”
SEC MD&A · August 5, 2026
The company has incurred significant losses and expects continued losses.
“We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future.”
SEC filings · January 15, 2025
There is substantial doubt about the company's ability to continue as a going concern.
“There is substantial doubt regarding our ability to continue as a going concern.”
SEC filings · January 15, 2025
The company has not generated any revenue from its development-stage products.
“We have not generated any revenue from our development stage products, and we do not know when, or if, we will generate any revenue.”
SEC filings · January 15, 2025
Risks & what to watch (3)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; needs additional financing [sec · filed 2025-01-15].
- No approved products or revenue — No products approved for sale; no revenue generated from development-stage products [sec · filed 2025-01-15].
- Dependence on partnerships — Pipeline relies on licensed technologies from research institutions; any disruption could impact development [sec_mda · as of 2026-08-05].
What to watch
- Ability to secure additional financing to fund operations and clinical development [sec · filed 2025-01-15].
- Progress of CAR T therapy programs for solid tumors in partnership with City of Hope and Nationwide Children's Hospital [sec_mda · as of 2026-03-19].
- Any regulatory updates or clinical trial results from pipeline candidates [sec_mda · as of 2026-08-05].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run MUSTANG BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MUSTANG BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
47.0 months
D/E 1.07 · 0% dilution
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$241K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 92,790 | $68K |
| blackrock, inc. | 84,745 | $62K |
| citadel advisors llc | 53,200 | $39K |
| vanguard capital management llc | 51,408 | $37K |
| vanguard fiduciary trust co | 32,120 | $23K |
| two sigma investments, lp | 16,754 | $12K |
| sbi securities co., ltd. | 509 | $371 |
| morgan stanley | 118 | $86 |
| cullen/frost bankers, inc. | 13 | $9 |
| bnp paribas financial markets | 6 | $4 |
Showing top 10 of 18 institutional holders of MUSTANG BIO, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.1%
- Days to cover
- 1.9
- Shares short
- 72,110
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for MUSTANG BIO, INC.?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on acquiring and developing novel cell and gene therapies for difficult-to-treat cancers, primarily through licensing partnerships with research institutions.
What is MUSTANG BIO, INC.'s lead drug candidate?
MUSTANG BIO, INC.'s most advanced tracked candidate is mb-101 (Phase 1) for IL13Rα2+ recurrent/refractory malignant glioma, glioblastoma (GBM), and high-grade astrocytoma.
Who is the CEO of MUSTANG BIO, INC.?
Dr. Manuel Litchman M.D. is the chief executive officer of MUSTANG BIO, INC. (MBIO).
Where is MUSTANG BIO, INC. headquartered?
MUSTANG BIO, INC. (MBIO) is headquartered in Waltham, MA, United States.
What therapeutic areas does MUSTANG BIO, INC. focus on?
MUSTANG BIO, INC. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.